A study on nonmelanoma patients with a BRAF mutation treated with vemurafenib found that the response rates of non‐small cell lung cancer and Erdheim‐Chester disease or Langerhans cell histiocytosis with a BRAF mutation were 42% and 43%, respectively.44 Here, BRAF is linked to lung cancer.